Latest News
Final Results for the Year Ended 31 December 2019
18 June 2020
Extension of At the Market Sales Agreement
12 June 2020
Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the agreement of an extension to the current At the Market Sales Agreement with ThinkEquity, a division of Fordham Financial Management, Inc.
As previously announced on 15 April 2020, Tiziana Life Sciences...
Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s disease
04 June 2020
Correction - Exercise of Warrants and Issue of Equity and Total Voting Rights
02 June 2020
The announcement (RNS Number: 6069O) released on 2 June 2020 at 07:00 am stated that 1,498,685 new ordinary shares will be issued yielding £710,843 in cash proceeds, the announcement should have stated the number of shares to be issued is...
Exercise of Warrants and Issue of Equity and Total Voting Rights
02 June 2020
London, New York, 2 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease...
Appointment of Broker
01 June 2020
FOR IMMEDIATE RELEASE
1 June 2020
Tiziana Life Sciences plc (AIM:TILS) is pleased to announce the appointment of Optiva Securities Limited as its broker with immediate effect.
Enquiries:
Gabriele Cerrone, Chairman and founder...